Acutaas Chemicals Limited (NSE: ACUTAAS | BSE: 543349)
Source: Acutaas Chemicals Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026) 📊 Stock Screeners
Acutaas Chemicals Limited (formerly known as Ami Organics Limited) is a Gujarat-headquartered, multi-vertical specialty chemicals enterprise built on over two decades of process chemistry expertise. The company operates as a research and development (R&D)-led manufacturer, transitioning from a generic active pharmaceutical ingredient (API) intermediate specialist into a diversified technology platform.
- Advanced Pharmaceutical Intermediates: Encompasses 500+ commercial products and 160+ global customers. Over 95% of the pharma intermediate portfolio is targeted toward chronic therapeutic areas (including cardiovascular, anti-psychotic, anti-depressant, anti-neoplastic, anti-retroviral, and non-steroidal anti-inflammatory applications). Key molecules are fully backward integrated up to N-1 process stages, providing 50% to 90% global market share in critical generic intermediates.
- CDMO Platform: The innovator custom development franchise validated 4 new NCE/CDMO molecules during FY 2025-26 alongside its anchor long-term supply contract with Fermion. The development pipeline added 30 to 40 new molecules during the year, advancing projects from early-stage synthesis to multi-ton late-stage clinical and commercial manufacturing.
- Battery Chemicals Division: Inaugurated Phase 1 at the Jhagadia complex in January 2026, establishing 2,000 MTPA installed capacity for Vinylene Carbonate (VC) and 2,000 MTPA for Fluoroethylene Carbonate (FEC). The entire Phase 1 commercial capacity is secured under 3-year long-term off-take customer contracts. The division maintains a development pipeline of 10+ battery additive products.
- Semiconductor Chemicals Division: Operated via Baba Fine Chemicals (1.8 KL reaction capacity in Greater Noida) and Indichem Inc. (South Korea). It manufactures extreme ultra-purity electronic-grade photoresist chemicals, etchants, and specialized polymer precursors operating at parts-per-billion (PPB) purity specifications.
📋 Quick Facts / Company Snapshot: Acutaas Chemicals Limited (NSE: ACUTAAS | BSE: 543349)
| Attribute | Disclosed Detail |
|---|---|
| Official Company Name | Acutaas Chemicals Limited |
| Corporate Identity Number (CIN) | L24100GJ2007PLC051093 |
| International Securities Identification Number (ISIN) | INE00FF01025 |
| Stock Exchange Listing | NSE: ACUTAAS | BSE: 543349 |
| Date of Incorporation / Founding Year | Formed as a partnership firm in 2004; Incorporated as a Private Limited Company on June 12, 2007; Rebranded to Acutaas Chemicals Limited in May 2025 |
| Founders / Key Founding Figures | Mr. Nareshkumar Ramjibhai Patel & Mr. Chetankumar Chhaganlal Vaghasia |
| Registered Office & Corporate Headquarters | Plot No. 440/4, 5 & 6, Road No. 82/A, GIDC Sachin, Surat – 394 230, Gujarat, India |
| Telephone & Investor Email | +91 75730 15366 / +91 72279 77744 | investorinfo@acutaas.com |
| Chairman & Managing Director | Mr. Nareshkumar Ramjibhai Patel (Executive Chairman & Managing Director) |
| CFO & Company Secretary | Mr. Bhavin N. Shah (Chief Financial Officer) | Mrs. Ekta Kumari Srivastava (Company Secretary & Compliance Officer) |
| Promoter & Holding Group | Patel & Vaghasia Promoter Family (Nareshkumar R. Patel & Chetankumar C. Vaghasia) |
| Industry / Sector Classification | Specialty Chemicals & Advanced Pharmaceutical Intermediates (NIC Code: 20119) |
| Total Employees & Workforce Structure | 1,007 Total On-Roll Employees (940 Permanent Employees, 67 Permanent Workers, 706 Contractual Workers) |
| Manufacturing Facilities & Operating Footprint | 5 Facilities across 2 Countries (Sachin, Ankleshwar, Jhagadia in Gujarat, India; Greater Noida, UP, India; Gongju, South Korea – Under Construction) |
| Credit Ratings & Rating Agency | CARE Ratings Limited: Long-Term Bank Facilities rated CARE A+ (Stable); Short-Term Bank Facilities rated CARE A1+ |
| Statutory, Secretarial, Cost & Internal Auditors | Statutory: M/s Maheshwari & Co. | Secretarial: M/s KSPS & Co. LLP | Cost: M/s Chirag Vallabhbhai Vekariya & Co. | Internal: M/s K. C. Mehta & Co. LLP |
| Registrar and Share Transfer Agent (RTA) | MUFG Intime India Private Limited (Formerly Link Intime India Private Limited), C-101, 247 Park, L.B.S. Marg, Vikhroli (West), Mumbai – 400083 |
🏢 The Corporate Identity: Acutaas Chemicals Overview, Promoters & History
The Big Picture: Business Model & Core Value Proposition
Acutaas Chemicals Limited (formerly known as Ami Organics Limited) is a Gujarat-headquartered, multi-vertical specialty chemicals enterprise built on over two decades of process chemistry expertise. The company operates as a research and development (R&D)-led manufacturer, transitioning from a generic active pharmaceutical ingredient (API) intermediate specialist into a diversified technology platform. Its core business spans advanced pharmaceutical intermediates, New Chemical Entity (NCE) development, semiconductor photoresist chemicals, battery electrolyte additives, and fine specialty chemicals.
The company’s commercial architecture operates on deep backward integration, with over 90% of its key pharmaceutical products derived internally from basic industrial feedstocks. By developing multi-step complex synthesis platforms—including continuous flow chemistry, microreactors, UV photochemistry, and slurry flow systems—Acutaas maintains dominant global market shares ranging from 50% to 90% in its anchor intermediate molecules. Its business model addresses four high-conviction end markets:
- Advanced Pharmaceutical Intermediates & CDMO: Catering primarily to fast-growing chronic therapeutic segments (cardiovascular, central nervous system, anti-diabetic, and oncology), supplying global innovator drug manufacturers and generic API producers.
- Semiconductor Chemicals: Operating through its majority-owned subsidiary Baba Fine Chemicals and South Korean joint venture Indichem Inc. to produce parts-per-billion (PPB) ultra-high-purity photoresist chemicals and electronic-grade processing agents.
- Battery Chemicals: Functioning as India’s pioneer commercial manufacturer of non-China sourced lithium-ion battery electrolyte additives, specifically Vinylene Carbonate (VC) and Fluoroethylene Carbonate (FEC).
- Specialty & Fine Chemicals: Upgrading legacy commodity product lines (such as parabens and methyl salicylate) into higher-margin, customer-qualified specialty chemical solutions.
The Founders, Promoters & Their Legacy
The operational and strategic leadership of Acutaas Chemicals Limited is anchored by its co-founders, Mr. Nareshkumar Ramjibhai Patel and Mr. Chetankumar Chhaganlal Vaghasia. Beginning as a modest partnership firm in 2004, the founders guided the enterprise through technical scale-ups, global regulatory accreditations, equity capital market listings, and international joint ventures.
- Mr. Nareshkumar Ramjibhai Patel (Executive Chairman & Managing Director): Promoted to lead the executive board, Mr. Patel brings over two decades of technical and commercial experience in process chemistry, market expansion, and capital allocation. Under his leadership, Acutaas expanded its global presence to over 55 countries and secured strategic partnerships with major innovator pharmaceutical conglomerates. He holds 1,44,83,327 equity shares (17.69% equity stake) in the company as of March 31, 2026.
- Mr. Chetankumar Chhaganlal Vaghasia (Executive Director): Co-founder of the organization, Mr. Vaghasia possesses 23 years of experience in specialty chemical manufacturing, supply chain logistics, human resource governance, and plant operations. He directly oversees human resources, procurement, IT, and dispatch operations across the group’s facilities. He holds 1,22,58,079 equity shares (14.97% equity stake) in the company as of March 31, 2026.
The Journey: Corporate History & Key Milestones
The evolutionary trajectory of Acutaas Chemicals Limited highlights a transition from lab-scale synthesis to an multi-plant industrial platform:
- 2004–2007: Founded as Ami Organics, a partnership firm; incorporated as Ami Organics Private Limited in June 2007 with its initial manufacturing unit in Sachin, Gujarat.
- 2011–2017: Received DSIR accreditation for its in-house R&D center; secured initial USFDA EIR (Establishment Inspection Report) for the Sachin facility; expanded warehousing and raw material storage infrastructure.
- 2018–2020: Acquired manufacturing facilities at Ankleshwar and Jhagadia from Gujarat Organics Limited; secured PMDA Japan Good Manufacturing Practice (GMP) certification for Unit 1 (Sachin) and Unit 2 (Ankleshwar); commissioned a centralized R&D center and solvent recovery facility.
- 2021: Successfully completed a landmark Initial Public Offering (IPO) and listed equity shares on the NSE and BSE.
- 2022–2023: Acquired a 55% controlling partnership stake in Baba Fine Chemicals, entering the semiconductor photoresist chemicals sector; established wholly-owned subsidiary Ami Organics Electrolytes Private Limited; commissioned a automated brownfield facility at Ankleshwar equipped with Distributed Control System (DCS) technology.
- 2024–2025: Awarded EcoVadis Gold and subsequently EcoVadis Platinum accreditation (ranking in the top 1% of assessed companies globally); completed equity share sub-division (1:2 stock split); formed Indichem Inc., a 75:25 joint venture in South Korea with J & Materials Co. Ltd. to construct an advanced semiconductor chemical facility in Gongju.
- 2025–2026: Officially rebranded from Ami Organics Limited to Acutaas Chemicals Limited; inaugurated Phase 1 of the commercial battery chemicals project at Jhagadia (2,000 MTPA capacity each for VC and FEC); achieved certified Great Place To Work® status and received Responsible Care certification from the Indian Chemical Council.
The Corporate Umbrella & Group Structure
Acutaas Chemicals Limited exercises governance over an international network of subsidiaries, step-down entities, partnership firms, and joint ventures designed to isolate specific sector capabilities:
- Acutaas Advance Material Limited (Formerly Baba Advance Materials Limited): Wholly-owned Indian subsidiary executing strategic investments and capital allocations for the group’s semiconductor initiatives.
- Acutaas Chemicals Electrolytes Private Limited (Formerly Ami Organics Electrolytes Private Limited): Indian subsidiary dedicated to manufacturing and commercializing battery chemicals and electrolyte additives (holding 100% equity stake through FY26, diluted to 90% in May 2026).
- Baba Fine Chemicals: Partnership firm in Greater Noida, UP, in which Acutaas holds a 55% controlling economic interest, serving as India’s sole domestic manufacturer of ultra-high-purity photoresist chemicals.
- Indichem Inc.: Step-down foreign subsidiary incorporated in Gongju, South Korea (75% equity held via Acutaas Advance Material Limited and 25% by J & Materials Co. Ltd.) constructing a semiconductor chemicals production hub and operating an active R&D center.
- Enchem Ami Organics Private Limited: Step-down domestic subsidiary focused on battery chemical commercialization.
- Ami Onco-Theranostics, LLC: 50:50 joint venture entity registered in Delaware, USA, focusing on oncology therapeutic research.
⚙️ The Business Engine: Acutaas Chemicals Segments, Brands, Products & Operations
The Core Divisions & Segment Revenue Breakdown
Acutaas Chemicals Limited categorizes its business operations into two principal primary business segments under Ind AS 108: Advanced Pharmaceutical Intermediates and Specialty Chemicals. In FY 2025-26, total consolidated revenue from operations expanded by 33.02% year-on-year to reach ₹1,339.37 Crores, driven by the commercial scaling of its Contract Development and Manufacturing Organisation (CDMO) franchise.
| Business Vertical / Division | FY 2025-26 Revenue (₹ Cr) | % Share of Total Revenue | FY 2024-25 Revenue (₹ Cr) | Latest YoY (%) |
|---|---|---|---|---|
| Advanced Pharmaceutical Intermediates | 1,174.10 | 87.66% | 854.10 | +37.47% |
| Specialty Chemicals (Commodity, Semi & Battery) | 165.00 | 12.32% | 152.70 | +8.06% |
| Other Operating Revenue | 10.40 | 0.78% | 6.91 | +50.51% |
| Total Revenue from Operations | 1,339.37 | 100.00% | 1,006.88 | +33.02% |
The Product & Service Catalog (with Operational KPIs, Order Book & Customer Concentration)
The enterprise maintains a catalog of over 610 commercialized products sold to approximately 600 global customers across 55 countries. The operational backbone comprises a total installed reaction volume of ~1,100 KL across four multi-purpose Indian operational sites, supplemented by dedicated tonnage-scale continuous lines.
- Advanced Pharmaceutical Intermediates: Encompasses 500+ commercial products and 160+ global customers. Over 95% of the pharma intermediate portfolio is targeted toward chronic therapeutic areas (including cardiovascular, anti-psychotic, anti-depressant, anti-neoplastic, anti-retroviral, and non-steroidal anti-inflammatory applications). Key molecules are fully backward integrated up to N-1 process stages, providing 50% to 90% global market share in critical generic intermediates.
- CDMO Platform: The innovator custom development franchise validated 4 new NCE/CDMO molecules during FY 2025-26 alongside its anchor long-term supply contract with Fermion. The development pipeline added 30 to 40 new molecules during the year, advancing projects from early-stage synthesis to multi-ton late-stage clinical and commercial manufacturing.
- Battery Chemicals Division: Inaugurated Phase 1 at the Jhagadia complex in January 2026, establishing 2,000 MTPA installed capacity for Vinylene Carbonate (VC) and 2,000 MTPA for Fluoroethylene Carbonate (FEC). The entire Phase 1 commercial capacity is secured under 3-year long-term off-take customer contracts. The division maintains a development pipeline of 10+ battery additive products.
- Semiconductor Chemicals Division: Operated via Baba Fine Chemicals (1.8 KL reaction capacity in Greater Noida) and Indichem Inc. (South Korea). It manufactures extreme ultra-purity electronic-grade photoresist chemicals, etchants, and specialized polymer precursors operating at parts-per-billion (PPB) purity specifications.
- Commodity Fine Chemicals: Portfolio of 30+ products serving 400+ customers across 55 countries, producing fine chemical preservatives, parabens, methyl salicylate, and para-anisic acid, which are systematically being transitioned toward higher-margin technical applications.
- Sourcing & Customer Concentration: Raw material sourcing is highly localized, with 59% of inputs procured domestically within India, insulating operations from global maritime freight shocks. In compliance with Ind AS 108 disclosures, no single external customer accounted for more than 10% of total consolidated revenue in FY 2025-26.
The Names You Know: Key Brands & Flagship Portfolio
| Brand / Product Name | Category / Business Segment | Target Market & Key Positioning |
|---|---|---|
| Vinylene Carbonate (VC) | Battery Chemicals | Lithium-ion electrolyte additive enhancing cell life, thermal stability, and SEI layer formation. |
| Fluoroethylene Carbonate (FEC) | Battery Chemicals | High-voltage electrolyte additive for silicon-anode lithium-ion batteries and EV energy storage. |
| Photoresist Monomers & PAGs | Semiconductor Chemicals | Ultra-high-purity (PPB level) photochemical agents used in semiconductor wafer lithography. |
| N-1 Chronic Pharma Intermediates | Pharmaceutical Intermediates | Advanced multi-step precursors for cardiovascular, CNS, and anti-diabetic generic APIs. |
| Parabens & Methyl Salicylate | Specialty Fine Chemicals | Preservatives and active fine ingredients for global personal care, cosmetic, and pharma formulations. |
Mapping the Domestic & Global Reach (India vs. Exports)
Acutaas Chemicals Limited maintains a global commercial footprint, deriving over three-quarters of its operational revenues from foreign export markets. The company exports to ~55 countries, with major sales destinations including North America, Europe, Japan, South Korea, Taiwan, and Southeast Asia.
| Geographic Region | FY 2025-26 Revenue (₹ Cr) | % Share of Total Revenue | FY 2024-25 Revenue (₹ Cr) | Latest YoY (%) |
|---|---|---|---|---|
| International / Exports | 1,021.34 | 76.26% | 742.59 | +37.54% |
| Domestic (India) | 307.63 | 22.97% | 257.38 | +19.52% |
| Other Operating Income | 10.40 | 0.78% | 6.91 | +50.51% |
| Total Revenue from Operations | 1,339.37 | 100.00% | 1,006.88 | +33.02% |
The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices
The group operates five specialized manufacturing facilities and an accredited central research facility covering a total land area exceeding 92,835 square meters:
- Unit 1 (Sachin, Surat, Gujarat): 8,250 sq. mt. land area; 144 KL installed reactor capacity across 40 reactors, 17 dryers, and 13 production lines. Operates a Zero Liquid Discharge (ZLD) effluent treatment plant and Soil Biotechnology (SBT) system; USFDA EIR and PMDA GMP certified.
- Unit 2 (Ankleshwar, Gujarat): 10,375 sq. mt. land area; 442 KL installed reactor capacity across 80+ reactors. Fully automated multi-purpose plant operating on Distributed Control System (DCS) and Powder Transfer System (PTS) automation; PMDA Japan GMP certified.
- Unit 3 (Jhagadia, Bharuch, Gujarat): 56,698 sq. mt. land area; 512 KL reactor capacity (31 stainless steel and 14 glass-lined reactors) dedicated to fine specialty chemicals, alongside live Phase 1 battery chemicals capacity (2,000 MTPA VC and 2,000 MTPA FEC). Runs an advanced ETP and holds ISO-K Nuclear certification.
- Unit 4 (Greater Noida, Uttar Pradesh – Baba Fine Chemicals): 999 sq. mt. land area; 1.8 KL specialized reaction volume across 7 clean-room lab blocks. India’s single production base for electronic-grade photoresist chemicals.
- Unit 5 (Gongju, South Korea – Indichem Inc. JV): 16,513 sq. mt. land area; ultra-high-purity semiconductor chemical manufacturing asset currently under construction (slated for H2 CY2026 commissioning), supported by an active local R&D sampling center.
- Central R&D Center (Sachin, Surat): 2,200 sq. mt. DSIR-approved innovation center housing 130+ R&D staff (including 30+ PhD scientists), 4 advancement laboratories with 30 fume hoods, an 8-reactor automated pilot plant, and 43+ distinct chemical reaction capabilities.
- Renewable Energy Generation Asset (Vahelam, Bharuch & Narmada): 15.8 MW captive solar power infrastructure generating 52% of the total annual electricity consumed across the Ankleshwar and Jhagadia operating units.
📊 The Financial Health: Acutaas Chemicals Financial Statements & Numbers Simplified
Multi-Year Financial Highlights (₹ in Crores)
The multi-year financial performance reflects consistent revenue growth, operational leverage, and balance sheet expansion over a three-year period:
| Financial Metric | FY 2025-26 | FY 2024-25 | FY 2023-24 | Latest YoY (%) |
|---|---|---|---|---|
| Revenue from Operations | 1,339.37 | 1,006.88 | 717.50 | +33.02% |
| Operating EBITDA | 480.40 | 232.10 | 128.50 | +106.98% |
| EBITDA Margin (%) | 35.87% | 23.05% | 17.91% | – |
| Profit Before Tax (PBT) | 482.73 | 216.16 | 114.00 | +123.32% |
| Profit After Tax (PAT) | 356.37 | 160.42 | 80.80 | +122.15% |
| PAT Margin (%) | 26.61% | 15.93% | 11.26% | – |
| Total Equity / Net Worth | 1,710.75 | 1,320.08 | 858.90 | +29.59% |
| Capital Employed (Adjusted) | 1,753.15 | 1,347.01 | 950.40 | +30.15% |
| Return on Equity (RoE – Adjusted) (%) | 20.83% | 12.15% | 11.40% | – |
| Return on Capital Employed (RoCE – Adjusted) (%) | 25.35% | 15.25% | 15.10% | – |
| Operating Cash Flow | 292.17 | 118.34 | 98.40 | +146.89% |
Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)
| Consolidated Statement of Profit and Loss Line Item | FY 2025-26 (₹ Cr) | FY 2024-25 (₹ Cr) | Latest YoY (%) |
|---|---|---|---|
| Revenue from Operations | 1,339.37 | 1,006.88 | +33.02% |
| Other Income | 41.59 | 16.93 | +145.66% |
| TOTAL INCOME | 1,380.95 | 1,023.80 | +34.88% |
| Cost of Materials Consumed | 594.96 | 569.81 | +4.41% |
| Changes in Inventories of Finished Goods & WIP | (29.00) | (17.63) | +64.49% |
| Employee Benefits Expense | 117.57 | 83.66 | +40.53% |
| Finance Costs | 3.27 | 6.22 | -47.43% |
| Depreciation and Amortization Expense | 35.99 | 26.62 | +35.20% |
| Other Expenses | 175.44 | 138.96 | +26.25% |
| TOTAL EXPENSES | 898.23 | 807.64 | +11.22% |
| PROFIT BEFORE TAX (PBT) | 482.73 | 216.16 | +123.32% |
| Current Tax Expense | 117.20 | 49.19 | +138.26% |
| Deferred Tax Expense | 9.16 | 6.56 | +39.63% |
| PROFIT AFTER TAX (PAT) | 356.37 | 160.42 | +122.15% |
| Profit Attributable to Owners of the Company | 356.26 | 158.71 | +124.47% |
| Profit Attributable to Non-Controlling Interests | 0.11 | 1.70 | -93.53% |
| Other Comprehensive Loss (Net of Tax) | (3.22) | (0.14) | +2200.00% |
| TOTAL COMPREHENSIVE INCOME FOR THE YEAR | 353.14 | 160.28 | +120.33% |
Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)
| Consolidated Balance Sheet Line Item | FY 2025-26 (₹ Cr) | FY 2024-25 (₹ Cr) | Latest YoY (%) |
|---|---|---|---|
| Property, Plant and Equipment | 582.80 | 462.92 | +25.90% |
| Capital Work-in-Progress (CWIP) | 332.32 | 130.28 | +155.08% |
| Right-of-Use Assets | 50.52 | 42.39 | +19.18% |
| Goodwill | 104.34 | 56.80 | +83.70% |
| Intangible Assets | 7.19 | 8.28 | -13.16% |
| Non-Current Financial Assets – Investments | 0.20 | 0.20 | 0.00% |
| Other Non-Current Financial Assets (Security Deposits) | 8.22 | 4.93 | +66.73% |
| Non-Current Income Tax Assets (Net) | 0.00 | 0.15 | -100.00% |
| Other Non-Current Assets (Capital Advances) | 17.10 | 51.67 | -66.91% |
| Total Non-Current Assets | 1,102.69 | 757.63 | +45.54% |
| Inventories | 231.32 | 179.94 | +28.55% |
| Trade Receivables | 362.56 | 290.49 | +24.81% |
| Cash and Cash Equivalents | 215.55 | 185.22 | +16.38% |
| Bank Balances Other than Cash & Cash Equivalents | 9.28 | 63.70 | -85.43% |
| Current Financial Assets – Loans | 2.60 | 2.16 | +20.37% |
| Other Current Assets | 59.95 | 70.11 | -14.49% |
| Total Current Assets | 881.27 | 791.64 | +11.32% |
| TOTAL ASSETS | 1,983.96 | 1,549.26 | +28.06% |
| Equity Share Capital | 40.94 | 40.93 | +0.02% |
| Other Equity | 1,612.63 | 1,268.69 | +27.11% |
| Equity Attributable to Owners of the Company | 1,653.56 | 1,309.63 | +26.26% |
| Non-Controlling Interests | 57.19 | 10.45 | +447.27% |
| Total Equity (Net Worth) | 1,710.75 | 1,320.08 | +29.59% |
| Non-Current Financial Liabilities – Lease Liabilities | 9.11 | 4.75 | +91.79% |
| Non-Current Provisions | 4.59 | 2.55 | +80.00% |
| Deferred Tax Liabilities (Net) | 28.71 | 19.63 | +46.26% |
| Total Non-Current Liabilities | 42.40 | 26.93 | +57.45% |
| Current Borrowings (Short-Term Loans) | 26.49 | 8.18 | +223.84% |
| Trade Payables – MSME Dues | 27.18 | 54.32 | -49.96% |
| Trade Payables – Other Creditors | 126.72 | 101.72 | +24.58% |
| Other Current Liabilities | 12.44 | 13.48 | -7.72% |
| Current Provisions | 32.50 | 24.54 | +32.44% |
| Current Tax Liabilities (Net) | 5.48 | 0.00 | N/M |
| Total Current Liabilities | 230.81 | 202.25 | +14.12% |
| Total Liabilities (Excluding Equity) | 273.21 | 229.18 | +19.21% |
| TOTAL EQUITY AND LIABILITIES | 1,983.96 | 1,549.26 | +28.06% |
Working Capital Cycle & Schedule III Statutory Ratio Explanations
Working capital efficiency remained steady during FY 2025-26, with the net working capital cycle shifting modestly from 114 days to 120 days despite a 33.02% scale-up in operational turnover.
| Statutory Financial Ratio | FY 2025-26 | FY 2024-25 | Management Explanation for Variance >25% | Latest YoY (%) |
|---|---|---|---|---|
| Current Ratio | 3.82x | 3.91x | Variability within normal operating range. | -2.30% |
| Debt-Equity Ratio | 0.02x | 0.01x | Slight increase in working capital credit utilization. | +100.00% |
| Debt Service Coverage Ratio (DSCR) | 120.06x | 30.08x | Significant expansion in operating cash earnings available for debt servicing. | +299.14% |
| Return on Equity (RoE) | 20.83% | 12.15% | Higher net profitability driven by CDMO margin expansion. | – |
| Inventory Turnover Ratio | 6.51x | 5.98x | Higher production and finished goods throughput. | +8.86% |
| Trade Receivables Turnover Ratio | 4.10x | 4.05x | Consistent collection timelines across export markets. | +1.23% |
| Trade Payables Turnover Ratio | 3.84x | 3.92x | Stable procurement settlement practices. | -2.04% |
| Net Capital Turnover Ratio | 2.20x | 1.79x | Higher revenue generation per rupee of net working capital. | +22.91% |
| Net Profit Ratio (%) | 356.37 | 15.70% | Substantial improvement in product mix and CDMO volume realization. | – |
| Return on Capital Employed (RoCE) | 25.35% | 15.25% | Higher EBIT contribution relative to capital base. | – |
Cash Flow: Tracking the Money Movement
| Consolidated Cash Flow Statement Activity | FY 2025-26 (₹ Cr) | FY 2024-25 (₹ Cr) | Latest YoY (%) |
|---|---|---|---|
| Profit Before Tax (PBT) | 482.73 | 216.16 | +123.32% |
| Operating Profit Before Working Capital Changes | 496.86 | 235.09 | +111.35% |
| Net Working Capital Adjustments | (93.12) | (69.01) | +34.94% |
| Direct Income Taxes Paid (Net) | (111.57) | (46.74) | +138.70% |
| Net Cash Generated from Operating Activities (A) | 292.17 | 118.34 | +146.89% |
| Purchase of Property, Plant & Equipment / CWIP / Intangibles | (327.98) | (194.64) | +68.51% |
| Net Redemption / (Placement) of Bank Fixed Deposits | 54.42 | (40.10) | N/M |
| Interest Received & Investment Adjustments | 7.62 | 10.80 | -29.44% |
| Net Cash Used in Investing Activities (B) | (265.94) | (223.94) | +18.76% |
| Net Proceeds / (Repayment) of Short-Term Borrowings | 18.31 | (94.82) | N/M |
| Repayment of Long-Term Debt / Lease Liabilities | (0.66) | (113.98) | -99.42% |
| Equity Share Capital & Premium Issued / QIP Proceeds | 0.01 | 499.39 | -100.00% |
| Finance Costs & Share Issue Expenses Paid | (1.28) | (17.19) | -92.55% |
| Equity Dividend Paid | (12.28) | (12.28) | 0.00% |
| Net Cash Generated from / (Used in) Financing Activities (C) | 4.10 | 261.12 | -98.43% |
| NET INCREASE / (DECREASE) IN CASH & CASH EQUIVALENTS (A+B+C) | 30.33 | 155.52 | -80.50% |
| Cash & Cash Equivalents at Beginning of the Year | 185.22 | 29.70 | +523.64% |
| Cash & Cash Equivalents at End of the Year | 215.55 | 185.22 | +16.38% |
Funding the Future: CapEx, CWIP, R&D Intensity & Net Foreign Exchange
The company executes a phased investment program spanning FY2023 through FY2030. Key highlights of CapEx, research commitments, and foreign exchange intensity include:
- Capital Expenditure & CWIP Deployment: Total capital expenditure deployed in FY 2025-26 reached ₹195.00 Crores (with gross cash additions to PPE and CWIP standing at ₹327.98 Crores). The capital outlay was directed toward Phase 1 of the Jhagadia battery chemicals facility, pilot plant expansion at Sachin, and captive solar assets. Capital Work-in-Progress (CWIP) as of March 31, 2026, stood at ₹332.32 Crores.
- R&D Expenditure Intensity: Total R&D expenditure for FY 2025-26 stood at ₹22.76 Crores (comprising ₹17.59 Crores in recurring revenue expenditure and ₹5.17 Crores in capital R&D investments), representing 1.72% of standalone operational revenue.
- Net Foreign Exchange Earnings (Section 134(3)(m)): On a standalone basis, total foreign exchange inflows (export proceeds) reached ₹968.34 Crores, while total foreign exchange outflows (raw material imports and capital goods) stood at ₹267.60 Crores, generating net foreign exchange earnings of ₹700.74 Crores.
👥 Power & Control: Acutaas Chemicals Governance, Leadership & Shareholding Pattern
The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)
The governance structure of Acutaas Chemicals Limited is overseen by an 8-member Board of Directors, comprising 50% Independent Directors (including 2 Women Independent Directors).
| Name of Director / KMP | Designation / Role | DIN | Category |
|---|---|---|---|
| Nareshkumar Ramjibhai Patel | Executive Chairman & Managing Director | 00906232 | Promoter Executive Director |
| Chetankumar Chhaganlal Vaghasia | Executive Director | 01375540 | Promoter Executive Director |
| Virendranath Mishra | Whole Time Director | 07815490 | Executive Director |
| Ram Mohan Lokhande | Whole Time Director | 08117035 | Executive Director |
| Girikrishna S. Maniar | Independent Director (Audit Committee Chair) | 07515981 | Non-Executive Independent Director |
| Hetal Madhukant Gandhi | Independent Director (NRC Committee Chair) | 00106895 | Non-Executive Independent Director |
| Richa Manoj Goyal | Independent Director (SRC & CSR Chair) | 00159889 | Non-Executive Independent Director |
| Dr. Anita Bandyopadhyay | Independent Director | 08672071 | Non-Executive Independent Director |
| Bhavin N. Shah | Chief Financial Officer (CFO) | KMP | Key Managerial Personnel |
| Ekta Kumari Srivastava | Company Secretary & Compliance Officer | KMP | Key Managerial Personnel |
Who Owns the Stock? Shareholding Pattern
As of March 31, 2026, the paid-up share capital of the company stood at ₹40,93,55,610 divided into 8,18,71,122 equity shares of face value ₹5 each. Institutional investors (Foreign Portfolio Investors, Mutual Funds, Insurance Companies, and AIFs) collectively hold 39.08% of the equity capital.
| Shareholder Category | Number of Equity Shares Held | % of Total Issued Equity Capital |
|---|---|---|
| Promoter & Promoter Group | 2,67,41,416 | 32.66% |
| Foreign Portfolio Investors (FPIs / Corporate) | 1,59,52,201 | 19.48% |
| Mutual Funds | 1,13,47,656 | 13.86% |
| Insurance Companies | 26,61,506 | 3.25% |
| Alternate Investment Funds (AIFs) | 20,37,472 | 2.49% |
| Government Pension Fund Global | 29,01,687 | 3.54% |
| Public / Non-Institutional Shareholders & Others | 2,02,29,184 | 24.72% |
| Total Issued Equity Shares | 8,18,71,122 | 100.00% |
🗺️ The Corporate Family Tree: Group Structure, Ratings & Contingent Liabilities
Subsidiaries, Associates, & Joint Ventures (Form AOC-1)
The corporate family tree encompasses domestic subsidiaries, foreign operating step-down entities, partnership firms, and international joint ventures (financial figures as reported in Form AOC-1 in ₹ Crores):
| Entity Name | Relationship Type | Country | % Shareholding | FY 2025-26 Turnover (₹ Cr) | FY 2025-26 Net PAT (₹ Cr) |
|---|---|---|---|---|---|
| Acutaas Chemicals Electrolytes Pvt. Ltd. | Wholly-Owned Subsidiary | India | 100.00%* | 0.02 | (3.73) |
| Acutaas Advance Material Limited | Wholly-Owned Subsidiary | India | 100.00% | 0.00 | (2.12) |
| Baba Fine Chemicals | Partnership Entity | India | 55.00% | 15.59 | 3.25 |
| Indichem Inc. | Step-Down Foreign JV | South Korea | 75.00% | 0.19 | (5.39) |
| Enchem Ami Organics Private Limited | Step-Down Subsidiary | India | 100.00% | 0.00 | (0.00) |
| Ami Onco-Theranostics, LLC | Joint Venture | USA | 50.00% | 0.00 | 0.00 |
*Holding diluted to 90% in May 2026. **Held via Acutaas Advance Material Limited.
Strategic Investments, Credit Ratings, Banking Consortium & Contingent Liabilities
- Strategic Treasury Investments: Holds non-current equity investments in environmental infrastructure projects, including Globe Enviro Care Limited (74,171 shares; ₹0.10 Crore), Narmada Cleantech Limited (82,176 shares; ₹0.09 Crore), Sachin Industrial Co-Operative Society (3,012 shares; ₹0.004 Crore), and Bharuch Enviro Infrastructure Limited (1,260 shares; ₹0.001 Crore). Total unquoted carrying value stands at ₹0.20 Crore.
- Credit Ratings Profile: Rated by CARE Ratings Limited. Long-term bank facilities (term loans/facilities) are rated CARE A+ with a Stable outlook; short-term bank facilities (working capital/trade facilities) are assigned CARE A1+.
- Banking Consortium: Working capital and credit facilities are maintained across Axis Bank Limited, HDFC Bank Limited, ICICI Bank Limited, and DBS Bank Limited.
- Contingent Liabilities & Capital Commitments: Total estimated capital commitments remaining to be executed (net of capital advances) stood at ₹39.44 Crores as of March 31, 2026 (down from ₹80.27 Crores in FY25). Off-balance sheet bank guarantees issued by lenders stood at ₹1.33 Crores.
🎯 The Strategic Outlook: Competitive Moats, Risks, Growth Plans & FAQs
Competitive Advantages & Economic Moats
- Process Chemistry Moat & Backward Integration: Over 90% of key active intermediates are backward integrated from basic industrial feedstocks. Process engineering capabilities—spanning 43+ reaction chemistry classes, flow reactors, and UV photochemistry—enable market share leadership (50% to 90%) in key global intermediate molecules.
- First-Mover Non-China Battery Chemicals Platform: India’s pioneer commercial manufacturer of non-FEOC (ex-China) compliant electrolyte additives (Vinylene Carbonate and Fluoroethylene Carbonate). With Phase 1 capacity fully contracted for 3 years, Acutaas is positioned to supply global battery cell gigafactories expanding under the US Inflation Reduction Act / FEOC guidelines and India’s ACC PLI scheme.
- Semiconductor Hub Footprint via South Korea: India’s sole commercial manufacturer of electronic-grade photoresist chemicals (Baba Fine Chemicals). The Gongju, South Korea joint venture (Indichem Inc.) places the company directly inside the semiconductor ecosystem anchored by Samsung and SK Hynix, enabling ‘Just-in-Time’ local technical validation.
- High Entry Barriers & Global Regulatory Accreditations: Manufacturing facilities hold active USFDA Establishment Inspection Reports (EIR) and PMDA Japan GMP certifications without critical audit observations, complemented by 21 CFR-compliant QA systems, ISO certifications, and EcoVadis Platinum rating.
What Could Go Wrong? Key Challenges & Business Risks
- Geopolitical Shipping & Feedstock Disruption: Geopolitical friction in the Middle East and the closure of the Strait of Hormuz present risk to global maritime logistics, extending Gulf-Asia transit times by 8 to 12 days and increasing chemical feedstock import costs.
- Capex Execution & Customer Off-Take Timelines: Multi-year CapEx deployments in South Korea (Indichem Inc.) and Jhagadia Phase 2 battery chemicals entail project execution, equipment lead-time, and customer qualification risks before revenue generation.
- Customer Concentration in Emerging Verticals: Early-stage operations in battery chemicals and semiconductor materials rely on a concentrated group of tier-1 customers, where qualification delays could impact asset turnover.
The Next Chapter: Growth, Order Pipeline & CapEx Initiatives
The strategic agenda for FY 2026-27 and beyond focuses on expanding the high-margin CDMO franchise while scaling commercial production across newly commissioned specialty verticals:
- CDMO Franchise Expansion: Following the validation of 4 new CDMO products during FY 2025-26, the pipeline includes 30 to 40 additional molecules progressing toward clinical scale-up. The company is investing ₹25.00 Crores to construct a high-potent API (HPAPI) pilot plant at Sachin to support late-stage NCE projects.
- Commercialization of Battery Additives Phase 1 & Phase 2 Expansion: Phase 1 capacity at Jhagadia (2,000 MTPA VC and 2,000 MTPA FEC) is ramping up commercial production backed by 3-year off-take agreements. Phase 2 expansion is progressing to introduce two additional electrolyte additive molecules during FY 2026-27.
- Commissioning of South Korean Semiconductor Asset: Indichem Inc.’s manufacturing facility in Gongju, South Korea, is scheduled for commercial commissioning in H2 CY2026, transitioning from sample evaluation to full commercial supply for leading East Asian semiconductor fabs.
- Electronic Grade Chemicals Expansion: The Board of Directors on August 22, 2026, approved a new CapEx program of up to ₹212.00 Crores to build up to 81,000 MTPA of new electronic-grade chemical manufacturing capacity.
The Verdict: Strategic Outlook & Conclusion
Acutaas Chemicals Limited has successfully evolved from a specialized domestic intermediate manufacturer into a global specialty chemistry platform. By maintaining capital discipline—allocating CapEx primarily against contracted demand—the enterprise achieved its highest-ever adjusted Return on Capital Employed (RoCE) of 39.30% and Return on Equity (RoE) of 32.50% in FY 2025-26, while maintaining a healthy balance sheet with net cash position of ₹198.30 Crores. With four growth drivers—Pharma CDMO, Battery Chemicals, Semiconductor Materials, and Specialty Fine Chemicals—Acutaas is positioned to capitalize on global supply chain diversification across healthcare and advanced technology industries.
Frequently Asked Questions (FAQs) About Acutaas Chemicals
Q1: What does Acutaas Chemicals Limited manufacture, and what are its core products?
Acutaas Chemicals Limited manufactures advanced pharmaceutical intermediates, New Chemical Entity (NCE) custom synthesis products, semiconductor photoresist chemicals, lithium-ion battery electrolyte additives, and fine specialty chemicals. Its key commercial products include Vinylene Carbonate (VC), Fluoroethylene Carbonate (FEC), electronic-grade photoresist monomers, N-1 chronic pharma intermediates, parabens, and methyl salicylate.
Q2: What were Acutaas Chemicals’ revenue and net profit in FY 2025-26?
In FY 2025-26, Acutaas Chemicals Limited reported consolidated revenue from operations of ₹1,339.37 Crores (a growth of 33.02% year-on-year compared to ₹1,006.88 Crores in FY 2024-25) and a consolidated Profit After Tax (PAT) of ₹356.37 Crores (a growth of 122.15% compared to ₹160.42 Crores in FY 2024-25).
Q3: Who are the promoters and Managing Director of Acutaas Chemicals Limited?
The company was co-founded by Mr. Nareshkumar Ramjibhai Patel (Executive Chairman & Managing Director) and Mr. Chetankumar Chhaganlal Vaghasia (Executive Director). The promoter family collectively holds a 32.66% equity stake in the company as of March 31, 2026.
Q4: Where are Acutaas Chemicals’ manufacturing facilities located, and what is its export share?
The company operates five manufacturing facilities: Unit 1 in Sachin (Surat, Gujarat), Unit 2 in Ankleshwar (Gujarat), Unit 3 in Jhagadia (Gujarat), Unit 4 in Greater Noida (Uttar Pradesh via Baba Fine Chemicals), and Unit 5 in Gongju (South Korea via Indichem Inc., under construction). In FY 2025-26, exports accounted for 76.26% of total operational revenues, serving customers in ~55 countries.
Q5: What is Acutaas Chemicals’ debt profile, credit rating, and net worth?
Acutaas Chemicals maintains a debt-light balance sheet with total short-term borrowings of ₹26.49 Crores and lease liabilities of ₹9.11 Crores, against total cash and cash equivalents (including bank balances) of ₹224.83 Crores (yielding a net cash position of ₹198.30 Crores). Total consolidated Equity (Net Worth) stood at ₹1,710.75 Crores as of March 31, 2026. Long-term bank facilities are rated CARE A+ (Stable) and short-term facilities are rated CARE A1+ by CARE Ratings Limited.
Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.
Official Site: https://www.acutaas.com